These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 21678342)

  • 1. Cardioprotective interventions for cancer patients receiving anthracyclines.
    van Dalen EC; Caron HN; Dickinson HO; Kremer LC
    Cochrane Database Syst Rev; 2011 Jun; 2011(6):CD003917. PubMed ID: 21678342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotective interventions for cancer patients receiving anthracyclines.
    van Dalen EC; Caron HN; Dickinson HO; Kremer LC
    Cochrane Database Syst Rev; 2008 Apr; (2):CD003917. PubMed ID: 18425895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotective interventions for cancer patients receiving anthracyclines.
    van Dalen EC; Caron HN; Dickinson HO; Kremer LC
    Cochrane Database Syst Rev; 2005 Jan; (1):CD003917. PubMed ID: 15674919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines.
    de Baat EC; Mulder RL; Armenian S; Feijen EA; Grotenhuis H; Hudson MM; Mavinkurve-Groothuis AM; Kremer LC; van Dalen EC
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD014638. PubMed ID: 36162822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Cheuk DK; Sieswerda E; van Dalen EC; Postma A; Kremer LC
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD008011. PubMed ID: 27552363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
    van Dalen EC; Raphaël MF; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD006647. PubMed ID: 25188452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
    van As JW; van den Berg H; van Dalen EC
    Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
    van Dalen EC; Raphaël MF; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006647. PubMed ID: 19160293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment including anthracyclines versus treatment not including anthracyclines for childhood cancer.
    van Dalen EC; Raphaël MF; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Jan; (1):CD006647. PubMed ID: 21249679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
    van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005008. PubMed ID: 17054232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy.
    van Dalen EC; van der Pal HJ; Kremer LC
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD005008. PubMed ID: 26938118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy.
    van Dalen EC; van der Pal HJ; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2009 Oct; (4):CD005008. PubMed ID: 19821337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis.
    Shaikh F; Dupuis LL; Alexander S; Gupta A; Mertens L; Nathan PC
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26598513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    van Dalen EC; Caron HN; Kremer LC
    Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR; Spencer CM
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
    Pouillart P
    Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Jones RL
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.